• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Biocorrx Inc New (OP:BICX)

    0.3775 +0.0475 (+14.39%)
    Streaming Delayed Price Updated: 10:11 AM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 152
    Open 0.3775
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.3300
    Today's Range 0.3775 - 0.3775
    52wk Range 0.2044 - 0.5200
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Intellectual Property
    BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
    Issued Patent Supports BioCorRx’s Growing Portfolio of Implant-based Naltrexone Technologies 
    Via TheNewswire.com
    Topics Intellectual Property

    Performance

    YTD
    +28.4%
    +28.4%
    1 Month
    +55.2%
    +55.2%
    3 Month
    +24.3%
    +24.3%
    6 Month
    +9.1%
    +9.1%
    1 Year
    +4.9%
    +4.9%

    More News

    Read More
    News headline image
    BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
    Via NewMediaWire
    BioCorRx Announces Appointment of Louis Lucido as Board Chair
    Via TheNewswire.com
    News headline image
    BioCorRx Announces Appointment of Louis Lucido as Board Chair
    Via NewMediaWire
    BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
    Via TheNewswire.com
    Topics Regulatory Compliance
    BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
    Via TheNewswire.com
    BioCorRx Reports Business Update for the First Quarter of 2025
    Via TheNewswire.com
    Topics Death
    News headline image
    BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
    Via NewMediaWire
    Topics Regulatory Compliance
    News headline image
    BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
    From Virtual Investor Conferences; BioCorRx Inc.
    Via GlobeNewswire
    News headline image
    Life Sciences Virtual Investor Forum Agenda Announced for December 11th
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
    Via NewMediaWire
    News headline image
    BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
    Via NewMediaWire
    Topics Death
    BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
    Via TheNewswire.com
    Topics Death
    News headline image
    BioCorRx Reports Business Update for the First Quarter of 2025
    Via NewMediaWire
    Topics Death
    News headline image
    BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
    Via NewMediaWire
    BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
    Via TheNewswire.com
    News headline image
    BioCorRx Reports Business Update for the Second Quarter of 2024
    Via NewMediaWire
    Topics Intellectual Property
    News headline image
    BioCorRx Reports Business Update for the First Quarter of 2024
    Via NewMediaWire
    Topics Death Intellectual Property
    BioCorRx Reports Business Update for the First Quarter of 2024
    Via TheNewswire.com
    Topics Death Intellectual Property
    News headline image
    BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
    Via NewMediaWire
    Topics Intellectual Property
    BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
    Via TheNewswire.com
    Topics Intellectual Property
    News headline image
    BioCorRx Reports Business Update for 2023
    Via NewMediaWire
    Topics Death
    BioCorRx Reports Business Update for 2023
    Via TheNewswire.com
    Topics Death
    BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
    Via NewMediaWire

    Frequently Asked Questions

    Is Biocorrx Inc New publicly traded?
    Yes, Biocorrx Inc New is publicly traded.
    What exchange does Biocorrx Inc New trade on?
    Biocorrx Inc New trades on the OTC Traded
    What is the ticker symbol for Biocorrx Inc New?
    The ticker symbol for Biocorrx Inc New is BICX on the OTC Traded
    What is the current price of Biocorrx Inc New?
    The current price of Biocorrx Inc New is 0.3775
    When was Biocorrx Inc New last traded?
    The last trade of Biocorrx Inc New was at 06/02/26 10:11 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.